FDA grants priority review for Rubraca; Arpeggio snags $3.2M in seed financing
→ Months after the UK’s cost-effectiveness agency NICE had a change of heart on its drug Rubraca — Clovis has announced that the FDA granted priority review for its application to expand the use of the drug to patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer. The PDUFA date is May 15, 2020. Clovis’ shares $CLVS rose nearly 13.5% to $10.10 in Wednesday morning trading.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.